ESEmily Szabo

Emily Szabo

*This is an algorithmically generated author record based on publicly available information.

Emily Szabo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cryotherapy as Treatment for Chronic Rhinitis: Long‐Term Results of a Prospective, Multicenter Registry

    by Amber U. Luong, Neelesh H. Mehendale, Emily Szabo, Farhad Sigari, Anthony G. Del Signore, David M. Yen

    Objective: The purpose of this registry was to capture observational data on a large and diverse cohort treated with the ClariFix Cryotherapy device for chronic rhinitis. Study Design: Prospective, multicenter, nonrandomized, observational registry. Setting: Twenty‐two tertiary care and private otolaryngology practices. Methods: ClariFix treatment was administered to adult patients with allergic or nonallergic chronic rhinitis. Outcome measures included the reflective Total Nasal Symptom Score, mini Rhinoconjunctivitis Quality of Life Questionnaire, Patient Global Impression of Change, Clinician Global Impression‐Improvement, and adverse events related to the device or procedure through 24‐month follow‐up. Results: A total of 354 participants received 932 treatments. The mean change in total reflective Total Nasal Symptom Score from baseline to all follow‐ups was significant ( P < .001); greater than 73% of participants were responders, achieving ≥1 point reduction at all follow‐ups. Participants with baseline reflective Total Nasal Symptom scores ≥ 7 had greater improvement than those with baseline scores < 7 ( P < .001). Greater than 74% of participants were quality of life responders (≥0.4 points) at all follow‐ups with the mini Rhinoconjunctivitis Quality of Life Questionnaire. More than 73% of participants reported PGIC improvement at all follow‐ups. Clinicians noted improvement in 87.1% of participants at 3‐month follow‐up. No device‐ or treatment‐related serious adverse events were reported. Device‐ and treatment‐related adverse events were transient, nonserious, and typically resolved by over‐the‐counter medication and warm beverages. Conclusion: This registry provides additional long‐term evidence of the safety and efficacy of cryotherapy for the treatment of chronic rhinitis in a diverse population through 24 months.

  • Open Access

    Removal Forces of a Helical Microwire Structure Electrode

    by Amelia Howe, Zhanda Chen, Kyle Golobish, Victoria R. Miduri, Derrick Liu, David Valencia, Morgan McGaughey, Emily Szabo, Manfred Franke, Stephan Nieuwoudt

    (1) Background: Medical devices, especially neuromodulation devices, are often explanted for a variety of reasons. The removal process imparts significant forces on these devices, which may result in device fracture and tissue trauma. We hypothesized that a device’s form factor interfacing with tissue is a major driver of the force required to remove a device, and we isolated helical and linear electrode structures as a means to study atraumatic removal. (2) Methods: Ductile linear and helical microwire structure electrodes were fabricated from either Gold (Au) or Platinum–Iridium (Pt-Ir, 90-10). Removal forces were captured from synthetic gel models and following chronic implantation in rodent and porcine models. Devices were fully implanted in the animal models, requiring a small incision (<10 mm) and removal via tissue forceps. (3) Results: Helical devices were shown to result in significantly lower maximal removal forces in both synthetic gel and rodent studies compared to their linear counterparts. Chronically (1 yr.), the maximal removal force of helical devices remained under 7.30 N, for which the Platinum–Iridium device’s tensile failure force was 32.90 ± 2.09 N, resulting in a safety factor of 4.50. (4) Conclusions: An open-core helical structure that can freely elongate was shown to result in reduced removal forces both acutely and chronically.


  • Irreversible, self-aligned microfluidic packaging for chronic implant applications

    by Emily Szabo, Allison Hess-Dunning

    Packaging is an often overlooked component in microfluidic devices for biomedical implant applications. Robust and reliable connectors to interface microscale and macroscale features are especially critical for chronic implant applications. Existing microfluidic packaging methods are incompatible with emerging polymeric materials designed to enhance device integration with the surrounding tissue. A microfluidic connector scheme was developed to promote compatibility with novel materials and implant applications. The connectors and an adhesive wax were printed on a scaffold via additive manufacturing processes. The low-temperature packaging process entailed bonding the connector to a polymer nanocomposite-based intracortical microfluidic probe using an adhesive wax. The robustness of the packaging was assessed by measuring the tensile and shear bond strengths of the connector-adhesive wax-polymer film interface. After soak testing for 4 weeks, the bond strength continued to exceed the force required to infuse fluids through the microfluidic channel. Further, the shear bond strength exceeded typical probe insertion forces by at least ten-fold. These results support the use of the connector and thermal bonding method as a viable option for chronic implant applications.